The global pulmonary drug delivery systems market was US$ 53267.55 in 2021. The global pulmonary drug delivery systems market is forecast to reach US$ 91,128.65 million by 2030, growing at a compound annual growth rate (CAGR) of 7% during the forecast period from 2022 to 2030.
"Targeted drug delivery" means to direct drugs toward the target site. Pulmonary drug delivery is a targeted drug delivery system that delivers the drug moiety to the lower respiratory tract. As the name suggests, pulmonary drug delivery refers to the process of administering drugs through the lungs. Inhalation is a more effective method of administering drugs for asthma and chronic obstructive pulmonary disease. The delivery of pulmonary medicines offers immediate relief from asthmatic attacks and acute bronchitis. Pulmonary aerosols are a particular type of device that delivers drugs to the lungs.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The outbreak of COVID-19 had a positive impact on the global pulmonary drug delivery systems market. People with Chronic Obstructive Pulmonary Diseases and asthma were at higher risk of death from COVID-19. Globally, the COVID-19 pandemic has put tremendous pressure on healthcare systems, which has led to the need for diagnostic tools & treatment facilities. Many clinics and hospitals throughout the world restructured their operations to accommodate the increasing number of patients diagnosed with COVID-19. More hospitals had increased the number of diagnoses. The COVID-19 pandemic may have altered a patient's response to respiratory symptoms, making them less likely to seek treatment. As a result, the global market has grown significantly.
Regional Insights
In 2021, North America dominated the pulmonary drug delivery systems market and is forecast to continue dominating during the forecast period. The increasing prevalence of pulmonary diseases, the presence of key players in the manufacturing and development of pulmonary disease drugs, the growth of hospitals and diagnostic centers, and government initiatives to improve the treatment of pulmonary disease in the region all contribute to this growth.
Asia-Pacific is forecast to grow at the fastest CAGR during the forecast period. Due to the increasing prevalence of pulmonary diseases, the need for pulmonary drug delivery, and the development of different healthcare foundations in the region.
Leading Competitors
The leading prominent companies profile in the global pulmonary drug delivery systems market are:
Scope of the Report
The global pulmonary drug delivery systems market segmentation focuses on Product, Application, Distribution Channel, and Region.
Segmentation based on Product
Segmentation based on Application
Segmentation based on Distribution Channel
Segmentation based on Region